New combo therapy offers hope for hard-to-treat GI cancers
NCT ID NCT05205330
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two drugs (vorbipiprant and balstilimab) in people with advanced colorectal or other gastrointestinal cancers that have not responded to prior treatments. The goal is to see if the combination is safe and can shrink tumors or slow disease progression. About 107 participants will receive the treatment, and researchers will monitor side effects and tumor response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Azienda Ospedaliero Universitaria Pisana
Pisa, Pisa, 56126, Italy
-
Istituto Nazionale dei Tumori
Milan, Milano, 20133, Italy
-
Istituto Oncologico Veneto IRCCS
Padova, Padova, 35128, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication